PTK2 and prostate carcinoma: Recruitment and activation of Src, FAK and p130CAS by ligand-coupled steroid receptors has been described in different cell types [32], [34], [35], [45]–[47] and has been correlated to proliferative and survival effects of steroids in breast and prostate cancer cells [26], [35], [47].